Three pivotal trials, Prosper, Spartan and Aramis, have shown improved cancer control when treating patients with nmCRPC and low PSA doubling time. The definition of the non-metastatic stage is much depending on the sensitivity of the imaging test, rendering the non-metastatic stage as selection criteria weak. In this context, PSA gains a major role as selection criteria for treatment. On the other hand, in CRPC PSA has limitations in treatment monitoring and imaging might be a more reliable tool to decide when treatment needs to be changed. This webinar sheds light into the difficulties encountered with PSA and imaging when treating nmCRPC patients.
Publication date: June 2021
Available languages: English
Topic: Prostate Cancer
CME: This webinar is accredited with 1 European CME credit (ECMEC®) upon completion of the questionnaire after attending the live webinar
Duration: Approx. 60 – 90 minutes